Drug Trial Radar · NCT02660034
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
229
Actual
Start
Feb 2, 2016
Primary completion
Sep 9, 2020
Study completion Sep 9, 2020
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- Collaborators
- Myriad Genetic Laboratories, Inc.
- First posted
- Jan 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.
Conditions
- Solid Tumors
Interventions
TislelizumabBiological
PamiparibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number Of Participants Experiencing Adverse Events (AEs)Time frame: From Day 1 up to 4 years and 7 months
- Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)Time frame: 21 days following the first dose of tislelizumab and pamiparib in Cycle 1
- Part B: Objective Response Rate (ORR)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
- Part B: Progression-free Survival (PFS)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
- Part B: Duration Of Response (DOR)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
- Part B: Disease Control Rate (DCR)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
- Part B: Clinical Benefit Rate (CBR)Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
- Part B: Overall Survival (OS)Time frame: From Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
Pinnacle Oncology Hematology
Scottsdale, Arizona
Cedars Sinai Medical Center
Los Angeles, California
Rocky Mountain Cancer Centers
Denver, Colorado
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Roswell Park Cancer Institute
Buffalo, New York
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Oncology
Dallas, Texas
Texas Oncology
Tyler, Texas
Virginia Cancer Specialists
Fairfax, Virginia
The Canberra Hospital
Garran, Australian Capital Territory, Australia
Mid North Coast Cancer Institute
Coffs Harbour, New South Wales, Australia
Calvary Mater Newcastle
Newcastle, New South Wales, Australia
Westmead Hospital
Parramatta, New South Wales, Australia
Prince of Wales
Randwick, New South Wales, Australia
Northern Cancer Institute
St Leonards, New South Wales, Australia
Icon Cancer Care
Brisbane, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Linear Clinical Research Ltd
Nedlands, Western Australia, Australia
Institut Gustave Roussy
Paris, France
Centre Eugene Marquis
Rennes, France
Auckland City Hospital
Auckland, New Zealand
Capital and Coast District Health Board
Wellington, New Zealand
Hospital Universitario Vall d'Hebrón
Barcelona, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Sarah Cannon Research Institute
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.